Bone targeting agents: bisphosphonates

被引：11

作者：

Debiais, Francoise ^{[1
]}

机构：

[1] Univ Poitiers, CHU Poitiers, Serv Rhumatol, F-86021 Poitiers, France

来源：

BULLETIN DU CANCER | 2013年 / 100卷 / 11期

关键词：

bone metastases; bisphosphonates; malignant osteolysis; CANCER ADJUVANT THERAPY; LONG-TERM EFFICACY; BREAST-CANCER; ZOLEDRONIC ACID; AMERICAN-SOCIETY; SOLID TUMORS; DOUBLE-BLIND; TASK-FORCE; METASTASES; PAMIDRONATE;

D O I：

10.1684/bdc.2013.1840

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as adjuvant therapy before the onset of bone metastases is currently being evaluated.

引用

页码：1199 / 1206

页数：8

共 32 条

[1] Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].

Aapro, M. ;

Abrahamsson, P. A. ;

Body, J. J. ;

Coleman, R. E. ;

Colomer, R. ;

Costa, L. ;

Crino, L. ;

Dirix, L. ;

Gnant, M. ;

Gralow, J. ;

Hadji, P. ;

Hortobagyi, G. N. ;

Jonat, W. ;

Lipton, A. ;

Monnier, A. ;

Paterson, A. H. G. ;

Rizzoli, R. ;

Saad, F. ;

Thuerlimann, B. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :420-432

[2] Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial [J].

Amadori, Dino ;

Aglietta, Massimo ;

Alessi, Barbara ;

Gianni, Lorenzo ;

Ibrahim, Toni ;

Farina, Gabriella ;

Gaion, Fernando ;

Bertoldo, Francesco ;

Santini, Daniele ;

Rondena, Roberta ;

Bogani, Paola ;

Ripamonti, Carla I. .

LANCET ONCOLOGY, 2013, 14 (07) :663-670

[3]

[Anonymous], 2013, NCCN CLIN PRACT GUID

[4]

[Anonymous], 2017, COCHRANE DB SYST REV

[5]

[Anonymous], 2019, CLIN PRACTICE GUIDEL

[6] Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women [J].

Chlebowski, Rowan T. ;

Chen, Zhao ;

Cauley, Jane A. ;

Anderson, Garnet ;

Rodabough, Rebecca J. ;

McTiernan, Anne ;

Lane, Dorothy S. ;

Manson, JoAnn E. ;

Snetselaar, Linda ;

Yasmeen, Shagufta ;

O'Sullivan, Mary Jo ;

Safford, Monika ;

Hendrix, Susan L. ;

Wallace, Robert B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3582-3590

[7] Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results [J].

Coleman, R. ;

de Boer, R. ;

Eidtmann, H. ;

Llombart, A. ;

Davidson, N. ;

Neven, P. ;

von Minckwitz, G. ;

Sleeboom, H. P. ;

Forbes, J. ;

Barrios, C. ;

Frassoldati, A. ;

Campbell, I. ;

Paija, O. ;

Martin, N. ;

Modi, A. ;

Bundred, N. .

ANNALS OF ONCOLOGY, 2013, 24 (02) :398-405

[8]

Coleman RE, 2012, P AM SOC CLIN ONCOL, V30

[9] Breast-Cancer Adjuvant Therapy with Zoledronic Acid [J].

Coleman, Robert E. ;

Marshall, Helen ;

Cameron, David ;

Dodwell, David ;

Burkinshaw, Roger ;

Keane, Maccon ;

Gil, Miguel ;

Houston, Stephen J. ;

Grieve, Robert J. ;

Barrett-Lee, Peter J. ;

Ritchie, Diana ;

Pugh, Julia ;

Gaunt, Claire ;

Rea, Una ;

Peterson, Jennifer ;

Davies, Claire ;

Hiley, Victoria ;

Gregory, Walter ;

Bell, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) :1396-1405

[10]

Debiais F., 2008, REV RHUM, V75, P511

← 1 2 3 4 →